NUVATION BIO ANNOUNCES PUBLICATION OF POSITIVE PHASE 2 STUDY RESULTS FOR SAFUSIDENIB FOR THE TREATMENT OF GRADE 2 IDH1-MUTANT GLIOMA IN NEURO-ONCOLOGY

Reuters · 2d ago

Please log in to view news